AICAR vs Retatrutide
A side-by-side research comparison of AICAR and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AICAR | Retatrutide |
|---|---|---|
| Full name | AICAR (AMPK Activator / Exercise Mimetic) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | AICAR is converted intracellularly to ZMP, which mimics AMP and directly activates AMP-activated protein kinase (AMPK). AMPK activation shifts metabolism toward fat burning, mitochondrial biogenesis, and glucose uptake, mimicking effects of endurance exercise. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 258.23 Da | 5,200 Da (approximate) |
| Half-life | Short | 6 days |
| Bioavailability | Injection (research); poor oral | High (SubQ) |
| Typical dose | Not established for humans | 1-2 mg → titrate up to 12 mg |
| Frequency | Research only | Once weekly |
| Route | Injection (research) | Subcutaneous injection |
AICAR reported benefits
- AMPK activation (exercise-mimetic)
- Increased fat oxidation
- Mitochondrial biogenesis
- Improved endurance (animal models)
- Enhanced glucose uptake
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.